Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 3/20 | 0.61 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | HPGDS | O60760 | 1/20 | 0.51 |
| ▸ | KHK | P50053 | 1/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TOP2A | P11388 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13880649 | 0.96 | MAPK1 (0.58) | HTR4SMYD3MAPK1OPRK1HPGDS | |
| SCHEMBL13261136 | 0.92 | MAPK1 (0.62) | HTR4SMYD3MAPK1OPRK1HPGDS | |
| SCHEMBL13575605 | 0.92 | MAPK1 (0.62) | HTR4SMYD3MAPK1OPRK1HPGDS | |
| SCHEMBL29530960 | 0.92 | MAPK1 (0.62) | HTR4SMYD3MAPK1OPRK1HPGDS | |
| SCHEMBL2546256 | 0.92 | MAPK14 (0.52) | HTR4SMYD3MAPK1OPRK1HPGDS | |
| SCHEMBL1927002 | 0.91 | KMT2A (0.54) | HTR4MAPK1OPRK1MEN1KMT2A | |
| SCHEMBL12825174 | 0.91 | KMT2A (0.57) | MAPK1OPRK1MEN1KMT2AALPL | |
| SCHEMBL1926980 | 0.89 | KMT2A (0.59) | MEN1KMT2AALPL | |
| SCHEMBL13880856 | 0.88 | MAPK1 (0.56) | HTR4MAPK1OPRK1KHKMEN1 | |
| SCHEMBL13575620 | 0.88 | HPGD (0.51) | HTR4SMYD3HPGDSKHKPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114478539-B | Novel DCLK1 inhibitor and preparation method and application thereof | 中国人民解放军海军军医大学 | 2024-02-02 | — | — | CN | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018238-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| CN-114478539-A | Novel DCLK1 inhibitor and preparation method and application thereof | 中国人民解放军海军军医大学 | 2022-05-13 | — | — | CN | disclosed |
| US-20160347750-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| EP-2610256-A1 | Pyrimidine derivatives as protein kinase inhibitors | Cyclacel Limited (GB) | 2013-07-03 | — | — | EP | disclosed |
| EP-2564850-A1 | Polo-like kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2013-03-06 | — | — | EP | disclosed |
| EP-2079743-B1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-1983987-B1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009153197-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009141575-A1 | INHIBITORS OF PLK | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009130453-A1 | INHIBITORS OF PLK | CHROMA THERAPEUTICS LTD. (GB) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009067547-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009040556-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009042711-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |
| WO-2008050096-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008050078-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008040951-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2007095188-A2 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347750-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BRD3 | HTR4 4435/4885SMYD3 2868/4885MAPK1 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.